Lawyers for the FDA are expected to argue that pulling mifepristone would upend reproductive care for U.S. women and undermine the government’s scientific oversight of prescription drugs.
Related posts:
How Covid-19 could make Americans healthier
Will at-home abortions make Roe v. Wade obsolete?
Drugmakers brace for a rare Washington loss
CDC Director: Delta variant to ‘probably’ become dominant strain in U.S.
Covid-19 broke the CDC. Can Rochelle Walensky fix it?
Biden scraps plans to donate AstraZeneca vaccine abroad
Poll: Slim majority in U.S. backs return of masking
HHS unveils office to treat climate change as a health issue
Drug industry banks on its Covid clout to halt Dems’ push on prices
Anthony Fauci wants to put Covid’s politicization behind him
Pandemic overdose deaths spiked among people of color
Covid cases are skyrocketing again. States have no new plans.
